The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Evan P. Pisick
No Relationships to Disclose
 
Michael Rothe
Research Funding - Eisai; Pfizer
 
Pam K. Mangat
No Relationships to Disclose
 
Liz Garrett-Mayer
Consulting or Advisory Role - Deciphera; TYME
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Regeneron
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; Loxo; Merck; Rakuten Medical; Regeneron
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Lilly; Loxo; Merck (Inst); Oragenics; Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Jessica R. Bauman
Consulting or Advisory Role - AstraZeneca; Kura Oncology; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Trident Pharmaceuticals
 
Siqing Fu
Research Funding - Abbisko (Inst); Anaeropharma (Inst); Arrien Pharmaceuticals (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Hookipa Pharma (Inst); Huya Bioscience International (Inst); IMV (Inst); Innovent Biologics (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Medivir (Inst); Millennium (Inst); NCCN (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NIH/NCI (Inst); Novartis (Inst); NovoCure (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); Taiho Oncology (Inst); Tolero Pharmaceuticals (Inst); Turnstone Bio (Inst)
 
Rom S. Leidner
Consulting or Advisory Role - Merck; Oncolys BioPharma; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Ani Sarkis Balmanoukian
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Genentech/Roche (Inst); incyte (Inst); Merck (Inst); Seagen (Inst)
 
Carmen Calfa
No Relationships to Disclose
 
Daniel R. Carrizosa
Consulting or Advisory Role - Curio Science
Speakers' Bureau - Research to Practice
Research Funding - Aeglea Biotherapeutics (Inst); Celgene (Inst); Coordination Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst)
 
Stacy D. D'Andre
No Relationships to Disclose
 
Lisle Nabell
No Relationships to Disclose
 
Min S. Park
Stock and Other Ownership Interests - Abbvie (I); Johnson & Johnson (I); Merck (I); Pfizer (I)
Consulting or Advisory Role - Tempus
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Vyriad (Inst)
 
Ramya Thota
No Relationships to Disclose
 
Richard L. Schilsky
Consulting or Advisory Role - Cellworks; Scandion Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)